Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Average Target Price of $6.40 According to Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $6.40.

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price objective on the stock. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th.

Check Out Our Latest Analysis on MIST

Key Headlines Impacting Milestone Pharmaceuticals

These are some of the MIST headlines that stood out recently:

  • Positive Sentiment: CARDAMYST product revenue reached about $1.0 million, up 73% from the prior quarter, with roughly 3,400 prescriptions and coverage across about two-thirds of commercially insured lives. CARDAMYST and runway update
  • Positive Sentiment: The company plans to cut operating expenses by about 30%, while keeping its sales team and AFib-RVR Phase 3 program in place. It expects $145.4 million in cash and investments to fund operations into late 2028, beyond the trial’s anticipated second-half 2028 data readout. Company results and cost-efficiency measures
  • Negative Sentiment: The CFO and CMO have left the leadership team. Although cost reductions should conserve cash, the departures and the need to scale back spending may raise concerns about execution and commercialization. Cost-cutting and leadership update

Institutional Trading of Milestone Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RVW Wealth LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $994,000. Guardian Wealth Advisors LLC NC raised its position in shares of Milestone Pharmaceuticals by 21.1% during the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after buying an additional 59,200 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Milestone Pharmaceuticals during the first quarter valued at approximately $397,000. TRU Independence Asset Management 2 LLC bought a new stake in shares of Milestone Pharmaceuticals during the second quarter valued at approximately $201,000. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of Milestone Pharmaceuticals by 12.2% in the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after buying an additional 16,000 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock traded down $0.14 on Tuesday, hitting $0.52. 4,142,608 shares of the company’s stock were exchanged, compared to its average volume of 1,227,676. The company has a 50-day simple moving average of $0.80 and a 200-day simple moving average of $1.31. The stock has a market capitalization of $64.74 million, a PE ratio of -0.75 and a beta of 1.07. Milestone Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. The company had revenue of $2.96 million for the quarter, compared to the consensus estimate of $1.00 million. As a group, equities analysts anticipate that Milestone Pharmaceuticals will post -0.84 EPS for the current year.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

See Also

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.